Mebias Discovery
Biotechnology, 3675 Market St Ste 200, Philadelphia, Pennsylvania, 19104, United States, 1-10 Employees
Phone Number: 26********
Who is MEBIAS DISCOVERY
MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable G-protein Coupled Receptor ...
Read More
-
Headquarters: 3675 Market St Ste 200, Philadelphia, Pennsylvania, 19104, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from MEBIAS DISCOVERY
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Mebias Discovery
Answer: Mebias Discovery's headquarters are located at 3675 Market St Ste 200, Philadelphia, Pennsylvania, 19104, United States
Answer: Mebias Discovery's phone number is 26********
Answer: Mebias Discovery's official website is https://mebiasdiscovery.com
Answer: Mebias Discovery's revenue is Under $1 Million
Answer: Mebias Discovery's SIC: 2834
Answer: Mebias Discovery's NAICS: 325412
Answer: Mebias Discovery has 1-10 employees
Answer: Mebias Discovery is in Biotechnology
Answer: Mebias Discovery contact info: Phone number: 26******** Website: https://mebiasdiscovery.com
Answer: MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. By developing pathway-selective/biased drugs within well-understood mechanisms, the significant on-target adverse effects can be alleviated. Cell-based assays alone are inadequate to identify biased drugs. Mebias understanding of protein dynamics of GPCRs offers a unique advantage. Given our experience and access to two key technologies native GPCR purification and protein nuclear magnetic resonance our approach offers resolution to identify biased agonists that is lacking in other methodologies. We have delivered a series of biased mu opioid receptor scaffolds among which is an NME-stage compound. The Mebias platform significantly decreases the time and costs to deliver optimized leads; our biased mu-opioids were designed within one year. The pathway-selective GPCR landscape is wide open. Our initial areas of focus are CNS/Pain, Metabolic, and Inflammatory related disorders. Expertise / Assets Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which correlates ligand-induced dynamic conformation of GPCR to pathway specific signaling Differentiated mu-opioid receptor pre-development candidates for the treatment of neuropathic and nociceptive pain (respiratory depression/GI motility/tolerance), e.g. MEB-4906 Business Proposal Seeking co-development and/or license our mu-opioid drug candidates (one near IND ready) Research funding/collaboration for lead discovery of additional targets in selected disease areas
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month